Atea Pharmaceuticals (ATEA) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

Financial Status - Atea Pharmaceuticals had $839.7 million in cash and cash equivalents as of September 30, 2021, providing a cash runway through 2025[8] - The 2020 global HCV market was $4.1 billion, with the US accounting for approximately 50% of global DAA sales[40] - Best-in-class combination for Hepatitis C has potential for > $1B[41] COVID-19 - Bemnifosbuvir (AT-527) - Bemnifosbuvir is being developed as a preferred backbone for first combination with protease inhibitors for COVID-19[8] - In a Phase 2 hospitalized study, Bemnifosbuvir 500 mg BID resulted in a -0.7 log10 reduction in viral load vs placebo on Day 2 in high-risk, unvaccinated patients[33, 35] - In the MOONSONG Phase 2 trial, exploratory analyses in high-risk patients showed a potent viral load reduction at Day 3, with Cohort A (550 mg BID) showing -0.3 log10 vs placebo and Cohort B (1,100 mg BID) showing -0.9 log10 vs placebo[36, 37] - Atea plans to initiate a Phase 2/3 combination trial with a protease inhibitor in late 2022[63] Hepatitis C - Bemnifosbuvir & Ruzasvir - Atea has an exclusive worldwide license from Merck for Ruzasvir, a next-generation pan-genotypic NS5A inhibitor[43] - Bemnifosbuvir is approximately 10-fold more active than sofosbuvir in vitro against a panel of laboratory strains and clinical isolates of HCV genotypes 1–5[44] - Atea plans to initiate a bemnifosbuvir + Ruzasvir Phase 2 combination trial in late 2022[63] Dengue - AT-752 - Approximately 400 million people are estimated to be infected with Dengue annually[49, 50] - AT-752 Phase 1 study was completed, showing that AT-752 was well tolerated after either single or multiple doses in healthy subjects[54] - Atea plans to initiate a proof-of-concept program with initial data expected in late 2022[63]